Table 1 Rheumatoid arthritis (RA) patients’ characteristics.

From: Inhibitory activity of FOXP3+ regulatory T cells reveals high specificity for displaying immune tolerance in remission state rheumatoid arthritis

Parameters

Healthy Median ± IQR

Remission RA Median ± IQR

Active RA Median ± IQR

p value#

n (%)

7

14 (51.9%)

13 (48.1%)

–

Age

30 ± 3

57 ± 22

56 ± 19

0.776

Female (%)

71

100

92

0.334

WBC (cell/mm3)

6.94 ± 2.11

5.97 ± 2.69

6.59 ± 3.30

0.913

Lymphocyte (%)

30.29 ± 7.00

28.50 ± 9.25

26.00 ± 9.00

0.076

ESR (mm/h)

–

28.00 ± 23.75

54.00 ± 65.00

0.013*

ACPA/RF positivity (%)

–

64.29

84.62

0.007**

VAS (range)

–

0a, 10–30b

0–60

0.000***

DAS28 score

–

2.33 ± 1.94

3.78 ± 1.73

0.000***

Duration of remission (%)

–

14 (< 6 months); 64 (6–24 months); 22 (> 24 months)

–

–

Treatment (%)

Mono-therapy

–

7

–

–

Two DMARDs

–

36

40

–

Three DMARDs

–

57

60

–

  1. ACPA anti-citrullinated protein antibodies, DAS28 disease activity score-28, DMARD disease-modifying antirheumatic drug, ESR erythrocyte sedimentation rate, RF rheumatoid factor, VAS visual analog scale, WBC white blood cell count.
  2. Significance at *p value < 0.05, **p value < 0.01, ***p value < 0.0001.
  3. #Comparison of remission and active RA.
  4. aRemission state patients (n = 11).
  5. bLow disease activeity with clinical remission (n = 3).
Back to article page